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a b s t r a c t
Background: Despite treatment advances, there remains a significant risk of recurrence in ovarian cancer,
at which stage it is usually incurable. Consequently, there is a clear need for improved patient stratifi-
cation. However, at present clinical prognosticators remain largely unchanged due to the lack of repro-
ducible methods to identify high-risk patients.
Methods: In high-grade serous ovarian cancer patients with advanced disease, we spatially define a tu-
mour ecological balance of stromal resource and immune hazard using high-throughput image and spatial
analysis of routine histology slides. On this basis an EcoScore is developed to classify tumours by a shift
in this balance towards cancer-favouring or inhibiting conditions.
Findings: The EcoScore provides prognostic value stronger than, and independent of, known risk factors.
Crucially, the clinical relevance of mutational burden and genomic instability differ under different stro-
mal resource conditions, suggesting that the selective advantage of these cancer hallmarks is dependent
on the context of stromal spatial structure. Under a high resource condition defined by a high level of
geographical intermixing of cancer and stromal cells, selection appears to be driven by point mutations;
whereas, in low resource tumours featured with high hypoxia and low cancer-immune co-localization,
selection is fuelled by aneuploidy.
Interpretation: Our study offers empirical evidence that cancer fitness depends on tumour spatial con-
straints, and presents a biological basis for developing better assessments of tumour adaptive strategies
in overcoming ecological constraints including immune surveillance and hypoxia.
© 2019 The Authors. Published by Elsevier B.V.







Evidence before this study
In high-grade serous ovarian carcinoma there remains a clear
need for improved patient stratification, particularly to allow
for the identification of patients with higher risk of recurrence.
The combination of two measures: genetic diversity of neoplas-
tic cells and that of their surrounding microenvironment, has∗ Corresponding author: Dr Yinyin Yuan, Centre for Evolution and Cancer & Di-
vision of Molecular Pathology, 15 Cotswold Road, Sutton, London, SM2 5NG, United
Kingdom.
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f novel biomarkers. Despite overwhelming evidence on the im-
ortance of cancer mutational burden and aneuploidy in elic-
ting immunoreactivity, other factors shaping this process are
lusive.
dded value of this study
In this study, we demonstrated that the spatial architecture of
umour stroma is a key determinant in successful adaptation of
ancer to overcome microenvironmental constraints including im-
une surveillance and hypoxia, thereby providing new explana-
ions for the lack of specificity in current treatments of ovarian
ancer and offering new therapeutic strategies.nder the CC BY license. (http://creativecommons.org/licenses/by/4.0/)
























































































































amplications of all the available evidence
The interaction between cancer cells and their surrounding
ealthy tissue is vital for tumour growth and evolution. In partic-
lar, the ecological balance in the vicinity of cancer cells provides
ritical context to the assumption of different adaptive strategies
ithin cancer cell populations. This study has shown that the clin-
cal consequences of cancer hallmarks, mutagenesis and somatic
opy number alterations, also differ under specific tissue ecological
ontexts. Understanding the biological basis of these fundamentally
ifferent tumour ecological contexts could allow for the develop-
ent of novel targeted therapies, by leveraging the ways in which
ach context alters the evolutionary trajectory of the disease.
. Introduction
Ovarian cancer is diagnosed in more than 225,000 women per
ear worldwide and remains a significant cause of gynaecological
ancer mortality. High-grade serous ovarian carcinoma (HGSOC) is
he most commonly occurring histologic subtype of epithelial ovar-
an cancer. The majority of women continue to present at advanced
tages and the overall 5-year survival rate remains around 40%.
he current standard of care for newly diagnosed ovarian cancer
s a combination of optimal cytoreductive surgery and platinum-
ased chemotherapy. The recognition of the importance of ho-
ologous recombination deficiency and BRCA status in HGSOC is
hanging clinical practice with the use of PARP inhibitors [1,2]. De-
pite treatment advances, there remains a significant risk of recur-
ence at which stage ovarian cancer is usually incurable [3]. The
eed for improved patient stratification has fuelled the search for
ew prognostic markers and further subtype identification with
he aid of novel molecular signatures [4–6]. For example, among
he four transcriptional subtypes of HGSOC, the mesenchymal sub-
ype with a high amount of infiltrating stromal components such
s myofibroblasts and microvascular pericytes was associated with
articularly poor survival, and an immunoreactive subtype with
avourable outcome [4–6]. However, clinical prognosticators remain
argely unchanged due to the lack of reproducible methods to iden-
ify high-risk patients, in particular those who face rapid disease
rogression despite optimal debulking surgery [7,8].
A promising route for the development of further novel HG-
OC biomarkers is to exploit the interplay between cancer cells
nd their microenvironment, the significance of which in influ-
ncing the progression of HGSOC and other cancers has been
ighlighted extensively [9–13]. However, microenvironmental in-
uences on neoplastic cells depend on their spatial relationships
nd specific interactions with multiple types of cells. Therefore, a
ethodological assessment of this multi-way interplay to gain a
ystem-level, spatially-defined knowledge of the tumour microen-
ironment, may elucidate the selective advance of genetically het-
rogeneous cancer cells.
Because the ecology of an organism or cell can be broken down,
n the most general terms, into resources and hazards, our recent
onsensus statements recommended the development of an eco-
ogical index that is a composite of both the resources and hazards
or neoplastic cells in a tumour [14]. As the first demonstration
f such eco-index, this study brings together the concept of eco-
ogical habitats defined by a resource-hazard balance in the HG-
OC tumour microenvironment to interpret genetic heterogeneity
n cancer cells in situ. The tumour microenvironment is analogous
o the habitat of an organism [15–17]. Just as an organism must
nteract with its habitat and other organisms by utilizing resources
nd evading predators, cancer viability and likelihood of progres-
ion are modulated by similar selective pressures in its microenvi-
onment [15]. The theoretical basis for the importance of the mi-
roenvironment lies, therefore, in its determination of the resourceR) uptake and predatory hazards (H) for the neoplastic cells [18].
n HGSOC, endothelial cells and fibroblasts in the tumour stroma
ay support tumour growth by providing growth factors for can-
er cells [19], stimulating angiogenesis [20] in order for them to
btain more nutrients, and increasing their invasive potential [21].
n the other hand, high densities of both B cells and the CD8+ T-
ell infiltrate have been associated with a better prognosis in HG-
OC [22,23].
Using automated histology analysis, we recently showed that
high abundance of stromal cells that include fibroblasts and
ndothelial cells was correlated with poor overall survival, while
ymphocytic infiltrate was correlated with favourable prognosis in
varian cancer [24], consistent with a number of studies [4–6].
ased on these observations, we propose that stromal cells are
ssociated with the provision of ‘resources’ for cancer while lym-
hocytic infiltrate is largely a ‘predatory hazard’ in HGSOC. In this
tudy, we: i) define microenvironmental habitats in the spatial sur-
oundings of neoplastic cells, ii) test tumour ecology as a new type
f quantitative biomarker for HGSOC and its clinical value indepen-
ent of known clinical variables in two independent patient co-
orts, and iii) present evidence that cancer evolutionary strategy is
ependent on the ecological context.
. Materials and methods
.1. Sample set
Samples of treatment-naïve HGSOC tumours from two indepen-
ent, previously described studies were included as the discovery
N=505, image and genomic data) [6] and validation (N=77, im-
ge data only) [24] cohorts. Five-year overall survival rates were
vailable for all patients in both cohorts (Table S1). Patient con-
ent and ethical approval were obtained by the institutional re-
iew board of Sun Yat-Sen University Cancer Center and relevant
nstitutional review boards participated in the TCGA study. Patient
election criteria included Federation of Gynecology and Obstet-
ics (FIGO) stage III and IV disease, a lower bound of 0.3 mm2 for
he sample area consisting of tumour, availability of H&E-stained
istological images of surgically resected tumours and exclusion
f TCGA samples recently re-classified as non-HGSOC [25]. In the
iscovery cohort (N=505, 967 frozen sections, 469 patients with
wo sections each and 36 patients with one section each), avail-
ble clinical risk factors included debulking status (defined as ‘op-
imal’ if no residual disease larger than 1 cm is present after sur-
ical cytoreduction and ‘sub-optimal’ otherwise) (N=459); disease
tage; patient age; radiological response to primary treatment (RE-
IST 1.1 criteria) (N=360), and BRCA1/2 mutation (N=282), taken
s a germline or somatic mutation in either BRCA1 or BRCA2. Ad-
itionally in the discovery cohort, mutational burden scores were
vailable for N=287 patients; arm/chromosomal SCNA, defined as
he rate of whole arm or chromosome amplification/deletion in a
ample, for N=481 patients, directly downloaded from [34]; num-
er of telomeric allelic imbalances (NtAI), defined as the number
f sub-telomeric regions with allelic imbalance that start beyond
he centromere and extend to the telomere, for N=456 patients;
arge-scale transitions (LST), defined as the number of chromoso-
al breaks between adjacent regions of at least 10Mb for N=456
atients; loss of heterozygosity (HRD-LOH), defined as the num-
er of regions with LOH which are larger than 15Mb but shorter
han the whole chromosome, for N=456 patients; and mRNA ex-
ression profiles for N=454 patients. Available clinical data for all
atients in the validation cohort (N=77, one FFPE section per pa-
ient) included clinical factors such as tumour debulking status,
isease stage, and serum CA125 level and patient age at diagnosis.
dditionally for four tumours in the validation cohort, anti-VEGF
ntibody-stained serial sections were also available. All patients re-

























































ficeived platinum-based chemotherapy, and 94% in the discovery co-
hort and 88% in the validation cohort also received a taxane.
2.2. H&E image analysis
Whole-tumour section images were processed using a previ-
ously published image analysis pipeline [24] to detect individual
cancer, lymphocyte and stromal cell nuclei. Additional extension
to this pipeline including staining normalization [26] was used
for accommodating the staining variability presented in TCGA im-
ages. Cell classification was performed using a support vector ma-
chine with 97 morphological and textural features derived from
haematoxylin positive nuclei. Validation of the automated image
analysis was based on experiments involving five orthogonal data
types [27]. First, the balanced accuracy as an average of sensitiv-
ity and specificity of our classifier was evaluated and found to
be 80.6% for stromal cells, 850% cancer cells and 826% lympho-
cytes (based on a set of N=894 hand-annotated single cell nuclei).
Second, we found that automated cell scoring using our pipeline
was highly correlated with independent scoring provided by TCGA
pathologists (Fig. S1). Third, using gene expression data and enrich-
ment analysis [28–30], we identified significant associations be-
tween cell abundance and relevant functional pathways and bio-
logical processes including cell cycle and checkpoints for cancer
cells, chemokine and leukocyte transendothelial migration for lym-
phocytes, and matrisome and collagen formation for stromal cells,
supporting the biological relevance of automated image analysis
results. Fourth, tumour purity measures using the gene expression-
based method ESTIMATE [31] and copy number-based method AB-
SOLUTE [32] correlated with tumour cellularity, defined as the can-
cer cell abundance estimated from the image analysis, (ESTIMATE
r=044, P < 0001; ABSOLUTE, r=043, P < 0001). Finally, im-
munohistochemistry sections of cancer, lymphocyte and stromal
markers (CK7, CD3, and SMA) showed good concordance with H&E
image analysis results (Supplementary Methods).
2.3. Local ecological habitat classification and robustness
Following image analysis to obtain cell location data, a grid
of squares of width 100μm (20 pixels with a resolution of
5μm/pixel) was applied to each image. Squares were classified
into different ecological habitats based on the abundance of lym-
phocytes and stromal cells relative to the number of cancer cells
within the square (Fig. S2, Materials and Methods). For example,
a square with a high abundance of both stromal cells and lym-
phocytes was deemed a ‘high resource-high hazard’ habitat. The
threshold for defining high and low abundance of resource/stromal
cells for each square i was defined as follows:
histr = kstr × nic (1)
where thistr is the stromal cell threshold for square i, n
i
c is the num-
ber of cancer cells in square i and kstr is a constant. Similarly, the
threshold thi
lym
for hazard/lymphocytic abundance for each square
i was determined by:
hilym = klym × nic (2)
where klym is also a constant. The two constants kstr and klym were
chosen following random sampling of 100 squares from 100 ran-
domly selected tumours in the discovery cohort. From an ecolog-
ical perspective, the number of individuals in a trophic level gen-
erally decreases with trophic level. Applying this concept to lym-
phocytes as predators and cancer cells as prey, it follows that there
would typically be fewer lymphocytes, even within a high hazard
habitat, than the number of stromal cells in a high resource habi-
tat. Consequently, the value selected for klym should be higher thanhat of klym. In this work, a klym of 02 was chosen, which ap-
eared to split the habitats into two approximately equal groups
Fig. S2A).For stromal resource, a kstr of 05 was selected. It was
bserved that this threshold appeared to split the sample set such
hat approximately 25% of the habitats were defined as high re-
ource (Fig. S2B). Since some noise can be expected in the data
ue simply to the presence of stromal cells along the tumour mar-
in as part of the body’s natural response to a tumour, and thus
ot a manifestation of cancer-stromal crosstalk that benefits cancer
ells, a high kstr ensured this was minimized while still returning
wo sizeable groups of habitats defined by relative stromal abun-
ance. For the 469 patients in the discovery cohort for whom two
istological sections per tumour were available, the total number
f each habitat type as a weighted average from the two sections
as used.
.4. Spatial stability and scale tolerance of local EcoScore
To test the spatial stability of EcoScore, we first introduced in-
remental grid shifts, computed EcoScore and compared to the
riginal data, since slight shifts in the grid placement may result
n changes to the EcoScore value. We implemented shifts of 5,
0 and 15 pixels (25μm, 50μm and 75μm respectively) in both
and y in the original grid of squares of side length 20 pixels
100μm), for all samples in the validation cohort. In each case,
he 40th percentile was used to dichotomize continuous EcoScore
alues into high and low, as in the original data. None of the 77
atients changed EcoScore groups following any of the grid shifts.
he mean EcoScore was also computed after every grid shift, and
n all cases the change was less than 2% of the original value.
Next, we tested the spatial scale tolerance of local EcoScore by
arying the size of grid squares. We tested squares of side lengths
0, 40, 60 and 100 pixels (50μm, 200μm, 300μm and 500μm re-
pectively), and compared patient stratification at 40% to the origi-
al data derived using 20pixel (100μm) squares. For 40–60 pixels,
nly 3 patients changed groups, but this increased to 6 patients at
0 pixels and 100 pixels, thus making the 20–60pixel range the
ost stable for evaluating EcoScore. To maximize the spatial reso-
ution of our method, we opted for the smallest square size in this
ange, 20 pixels. Further details on robustness testing are given in
he Supplementary Sweave.
.5. Global ecological balance
To explore wide-ranging ecological impacts from resources and
azards for cancer in the tumour microenvironment, we computed
global EcoScore for every sample as follows. First, hotspot analy-
is [33] was applied to each whole-tumour section to identify sta-
istically significant spatial clustering in lymphocytes and stromal
ells, as described in Supplementary Methods. Next, for each habi-
at in the tumour, distances to the nearest lymphocyte and stromal
















represent the nearest distance to a lymphocyte and
tromal cell hotspot respectively for habitat i. It is effectively a ra-
io of the mean distance to a lymphocyte and stromal cell hotspot
or a habitat in the sample, and higher values indicate greater rel-
tive proximity to resource-rich regions.
.6. Survival analysis
To test the association of the local and global EcoScore with
ve-year overall survival, we constructed univariate and multivari-


















































































































ete Cox proportional hazards models for the discovery and vali-
ation cohorts. Every 5th percentile in the range 15–85% of the
coScore was evaluated as a dichotomizing threshold in a univari-
te Cox model in the discovery cohort. Patients were split into two
roups based on this threshold and their survival rates compared.
log rank P value of less than 0003 (α = 005 corrected for mul-
iple testing using the conservative Bonferroni method) was taken
s a significant result. Where multiple thresholds with a corrected
value less than 0003 were found, the threshold with the lowest
value was selected. Significant ecological factors were assessed in
he validation cohort by dichotomization at the same percentile.
.7. Other statistical methods
The two-sided Jonckheere trend test was used to determine as-
ociation between a continuous variable and an ordered categori-
al variable with more than two categories, whereas for a variable
ith two categories, ordered or otherwise, a two-sided Wilcoxon
ank sum test was used. The Spearman rank correlation test was
sed to test for association between two continuous variables.
. Results
.1. Automated histology image analysis enables spatial mapping of
cological habitats for HGSOC tumours
A total of 1051 haematoxylin and eosin (H&E)-stained, whole-
umour section images from 582 HGSOC patients from two inde-
endent cohorts were processed with our computational pipeline
or automated detection of cancer, lymphocyte and stromal cell nu-
lei (Materials and Methods). In both cohorts we observed an over-
ll pro-tumour effect of stromal cells and an anti-tumour effect of
ymphocytes (Fig. S3, Table 1, Materials and Methods). Therefore,
tromal cells could be responsible for the provision of ‘resources’
or cancer while lymphocytic infiltrate may largely be a ‘preda-
ory hazard’ in HGSOC. Based on this assumption, tumour regions
ontaining cancer cells were classified into one of four ecologi-
al habitat types: R+H+ (high resource-high hazard), R+H- (high
esource-low hazard), R−H− and R − H+ (Fig. 1). The four habi-
ats were defined by the abundance, relative to and in the vicin-
ty of cancer cells, of stromal cells as resource and lymphocytes
s predatory hazard for cancer (Materials and Methods, Fig. 2A).
urther, we identified statistically significant hotspots of resources
nd hazards in each sample (Materials and Methods), and com-
uted the shortest distance to each of these for every habitat in
he sample.
.2. The EcoScore is a strong prognostic factor for overall survival
We combined the ecological habitats into a single local eco-
ogical score for a tumour, the local ‘EcoScore’, that balances pro-
umour habitats against tumour-inhibiting habitats. We hypothe-
ized that the R+H− habitat presents the most permissive envi-
onment for cancer cells and therefore plays a tumour-promoting
ole, and that the R − H+ habitat will be primarily tumour-
nhibiting. The R+H+ habitat will favour cancer cells capable of
mmune evasion that thereby profit most from the abundant re-
ources. Hence, according to life history theory(18), we proposed
his habitat to be favourable for cancer cells. To systematically
easure the ecological influences occurring at the tumour-stroma
nterface, we defined the local EcoScore as follows: EcoScore =
R+H+ + R+H−
R−H+ . It should be noted that R − H− habitats, the most
bundant habitat in each sample (Fig. 2B), have been excluded
rom the local EcoScore formula. This is because the majority of the
− H− habitats were found in tumour nests containing very fewon-tumour cells (Fig. S4A) and are thus less relevant for cancer-
ost cell interaction. Furthermore, no clear between the abundance
f R − H− habitats and overall survival relationship was found
cross the two patient cohorts (Fig. S4B).
In addition, to test wide-ranging ecological effects from re-
ources and hazards, we computed a global EcoScore by taking the
atio of the mean shortest distances to lymphocyte and stromal
ell hotspots for a habitat in the sample (Materials and Methods).
e hypothesized that a higher value, indicating relatively greater
roximity to resource-rich regions, would be associated with lower
verall survival.
A high local EcoScore was associated with poor overall survival
n both the discovery and validation cohorts (Fig. 2C). The effect
as independent of known risk factors for HGSOC, including de-
ulking status, patient age, disease stage, BRCA mutation, serum
A125 level/gene expression, response to primary treatment, and
tromal and lymphocytic abundance (defined as the fraction of
ll detected cells that are stromal cells or lymphocytes respec-
ively) (Table 1). Moreover, among the microenvironmental mea-
ures including cell and habitat abundances, only local EcoScore
nd R+H− abundance were prognostic in both cohorts following
n optimal threshold search in the discovery cohort and correc-
ion for multiple testing (Fig. 2C, Table 1). However, local EcoScore,
ut not R+H− abundance, was prognostic independently of the
bove risk factors, despite its correlation with lymphocytic and
tromal cell abundance (Fig. S5A–B, Table 1). In a multivariate
odel in the discovery cohort consisting of all available risk fac-
ors for HGSOC as well as local EcoScore and cell and habitat
bundance measures found to be prognostic in the cohort, the lo-
al EcoScore was the only measure to provide independent prog-
ostic information (Fig. 2C). Spatial stability and scale tolerance
f local EcoScore were demonstrated through tests over a range
f parameters in its spatial configuration (Materials and Methods,
ig. 2D). Comparison with molecular subtypes that have been as-
ociated with the tumour microenvironment [5], the mesenchy-
al molecular subtype was found to be enriched in the high local
coScore tumours (P < 0.0001), whereas, Low local EcoScore tu-
ours had a significantly higher proportion of the immunoreactive
ubtype (P < 00001, Fig. S6A), consistent with their prognostic
mplications. When compared with global EcoScore that was also
rognostic for poor survival in the discovery cohort (P=0.0037,
able 1), local EcoScore had a much higher prognostic power. Fur-
hermore, global EcoScore was not prognostic in the validation co-
ort (P > 005, Table 1), thus the local EcoScore (henceforth re-
erred to as EcoScore) was selected for further analyses as the
tronger indicator of ecological balance in the tumour microenvi-
onment.
To assess further clinical relevance of the EcoScore, we tested
ts prognostic value in patients who had optimal tumour debulk-
ng surgery. In both cohorts, patients who had optimal debulk-
ng surgery could be stratified into low and high risk groups for
elapse-free survival using the EcoScore, which identified a sub-
roup with a significantly higher risk of relapse within two years
Fig. 2E). Patients who had optimal debulking surgery but with a
igh EcoScore had similar relapse-free survival to patients who had
ub-optimal debulking surgery (P > 0.05). However molecular sub-
ypes did not stratify patients who had optimal debulking surgery
n the TCGA cohort (P > 005, Fig. S6B), although the mesenchy-
al subtype has been previously associated with a lower rate of
ptimal debulking surgery [5].
.3. Tumour EcoScore and mutational burden co-define a strong
rognostic model
To identify the most relevant indicators of HGSOC ecology and
volution, we first tested the prognostic value of different genomic
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Fig. 1. An ecological resource-hazard characterization of high-grade serous ovarian carcinoma (HGSOC). (A) Our H&E image analysis pipeline, based on 104 quantitative
measures of cell nucleus texture and morphology to classify nuclei into cancer, lymphocyte and stromal cell nuclei and provides their spatial coordinates, is used to process
an H&E-stained ovary tumour sample (left) and map the distribution of the three cell types (middle). The sample is then divided into small regions using a grid of square
size 100μm. The abundance of lymphocytes and stromal cells is evaluated in each square that contains at least one cancer cell to determine its local ecological habitat
type. Spatial distributions of the four habitats in this tumour are shown in a heatmap (right, top) with colours corresponding to the example habitat images above. Also
shown is the grid-based habitat classification in one region of the tumour sample. In addition, hotspot analysis is performed to detect spatial clustering in lymphocytes
and stromal cells in each sample. The distances to the nearest lymphocyte and stromal hotspots are evaluated for every habitat type and indicated in the heatmap (right,
S. Nawaz, N.A. Trahearn and A. Heindl et al. / EBioMedicine 48 (2019) 224–235 229
Table 1
Univariate and multivariate 5-year overall survival analyses results in two independent cohorts of HGSOC patients with FIGO stage III and IV disease. The
univariate prognostic values of clinical risk factors and cell abundance measures, where available, in the two cohorts are listed, as are those of our ecological
measures found to be prognostic in both the discovery (TCGA, 2011) and validation (Lan et al., 2015) cohorts: abundance of the high resource-low hazard
(R+H−) habitat and the EcoScore. The independence of our ecological measures as prognostic markers was evaluated in a multivariate model including
risk factors found to be prognostic in the univariate setting in the given cohort. For the discovery cohort, this included age at diagnosis, BRCA1/2 mutation,
response to primary chemotherapy and lymphocytic and stromal cell abundance; for the validation cohort, this included stromal cell abundance and CA125
level at diagnosis. In the validation cohort, CA125 levels were obtained from blood; in the discovery cohort, data for serum CA125 level at diagnosis were
unavailable, hence the expression of MUC16, the gene encoding CA125, was used. Results for ecological measures found to be prognostic in univariate and
multivariate analyses in both cohorts are shaded. HR: hazard ratio; CI: confidence interval; N: total number of patients in the cohort included in this study;
AU: arbitrary units; p: log rank P value (p<0003 has been interpreted as a significant result).
Discovery, TCGA, N=505 Validation, Lan et al., N=77
HR (95% CI) p HR (95% CI) p
Univariate Local EcoScore 165 (126–216) 00002 291 (146–579) 00015
Global EcoScore 147 (113–192) 00037 150 (081–277) 0193
R+H+ habitat 079 (054–109) 0137 114 (048–269) 0773
R+H− habitat 164 (126–213) 00002 244 (133–450) 0003
R−H+ habitat 058 (045–076) <00001 078 (043–143) 0424
R−H− habitat 142 (106–189) 0017 057 (031–107) 0076
Stromal cell abundance 140 (105–185) 0020 241 (119–491) 0012
Lymphocytic abundance 066 (051–085) 0001 085 (047–156) 0606
Tumour debulking status 119 (090–157) 0230 175 (096–318) 0065
Age at diagnosis 102 (101–104) <00001 103 (100–107) 0053
Disease stage 132 (094–184) 0108 126 (049–319) 0631
BRCA1/2 mutation 053 (035–082) 00035 – –
CA125 level at diagnosis/MUC16 expression (AU) 103 (095–112) 0461 100 (100–100) 0003
Response to primary treatment
Complete response 027 (020–037) <00001 – –
Partial response 254 (175–368) <00001
Stable disease 167 (093–302) 0084
Progressive disease 453 (293–700) <00001
Multivariate Local EcoScore 215 (115–401) 0016 322 (127–815) 0014
R+H− habitat 128 (078–211) 0326 112 (052–245) 0770
Stromal abundance 098 (055–175) 0953 108 (042–279) 0871
Immune abundance 069 (041–115) 0151 – –
CA125 level at diagnosis – – 100 (100–100) 0006
Age at diagnosis 102 (100–103) 0117 – –
BRCA1/2 mutation 057 (035–092) 0023 – –

















































peasures in the TCGA cohort, including mutational burden, defined
s the number of non-synonymous somatic mutations; total arm
nd whole-chromosome somatic copy number alterations (SCNA);
34] number of telomeric allelic imbalances (NtAI); [35] large-
cale transitions (LST) [36], and loss of heterozygosity (HRD-LOH)
37] (Supplementary Methods). Focal somatic copy number al-
erations [34] was correlated with mutational burden (r=042,
< 00001), hence it was excluded from this analysis. SCNA, NtAI,
ST and HRD-LOH were not found to be prognostic for overall sur-
ival (all P > 005, Fig. 3A, Table S2). However, a high mutational
urden was associated with better prognosis and high lympho-
ytic abundance based on H&E image analysis (Fig. 3B-C; TCGA co-
ort 1: P=0006; TCGA cohort 2: P=0005, Fig. S7A), consistent
ith the notion of cytotoxic immune response to tumour neoanti-
en [38–40]. None of the genomic measures were found to cor-
elate with tumour cellularity, calculated as the proportion of cells
ithin a tumour region that are tumour cells, therefore this associ-
tion between mutational burden and lymphocytic abundance can-
ot be explained by abundance of non-tumour cells (all P > 005,
ig. S7B). In comparison, CD8A expression and the cytotoxic im-
une signature [34,41] were not associated with mutational bur-
en (Fig. 3C). EcoScore was not correlated with mutational bur-
en (P > 005, Fig. 3D), and provided independent prognostic
alue for further patient stratification (P=0002). Together, tu-
our EcoScore and mutational burden co-defined an aggressive m
ottom). This is used to determine the global ecological balance in a tumour Based on p
ymphocytes present a predatory ‘hazard’. (B) The local EcoScore is computed as the ba
coScore is the ratio of the mean distances to the nearest lymphocyte and stromal cell
resent an integrated characterization of HGSOC.ubgroup of HGSOC with a high ecological imbalance and low mu-
ational burden (low mutational burden, high EcoScore group vs.
thers: P=25×10−6, HR = 225 [159–318], Fig. 3E).
.4. Cancer adaptive strategy differs under specific ecological context
Since changes in mutational burden and genomic instability
ay have direct consequence in cancer fitness [42], we investi-
ated how mutational burden and SCNA changed under differ-
nt habitats to determine their selective advantage under differ-
nt ecological contexts. We observed significant associations be-
ween mutational burden and the abundance of R− (R − H+/−)
ut not the R+ (R+H+/−) habitats, suggesting that stromal re-
ource plays a role in immune response to neoantigens (Fig. 4A).
nlike mutational burden, SCNA, NtAI, LST and HRD-LOH were not
ound to correlate with the abundance of any ecological habitat
Supplementary Fig. S8A-D). However, when patients were divided
nto low (R − H+/−) and high (R+H+/−) resource groups based
n our spatial definition of resource (Fig. 4B), the association be-
ween mutational burden and survival was only observed in the
igh resource group (Fig. 4C), regardless of cut-offs used within
reasonable range (Materials and Methods). On the other hand,
CNA, while also not different between low and high resource tu-
ours (Fig. 4D), was found to be prognostic only among low re-revious findings, we propose that stromal cells act as ‘resources’ for cancer while
lance between tumour-promoting and tumour-inhibiting habitats, and the global
hotspots for a habitat in the sample. Together with genomic tumour analyses, we
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Fig. 2. Assessing the prognostic value and stability of EcoScore. (A) Kaplan-Meier plots display the prognostic value of global EcoScore, defined by the mean ratio of distance
to the nearest lymphocyte and stromal cell hotspots for a cancer habitat, for 5-year overall survival in two independent cohorts of HGSOC patients. Numbers outside
parentheses indicate group size and numbers inside parentheses indicate deaths. (B) Kernel density plots show the distribution of abundances of the four ecological habitats
in the TCGA (left) and Lan et al. (right) cohorts. Mean and standard deviation (s.d.) of each distribution are given in brackets in the legends. In both cohorts, the peak of
the R − H− distribution is shifted to the right of the others and the s.d. of this distribution is highest. (C) Kaplan-Meier plots display the prognostic value of local EcoScore,
defined by the balance of tumour-promoting habitats against tumour-inhibiting habitats, for 5-year overall survival in two independent cohorts of HGSOC patients. Numbers
outside parentheses indicate group size and numbers inside parentheses indicate deaths. (D) Top: Heatmap illustrating the correlations between local EcoScore computed for
each sample in the validation cohort following grid shifts of 0 (original), 25, 50, and 75μm. Each square in the grid is 100μm. Bottom: Heatmap illustrating the correlations
between EcoScore computed for each sample in the validation cohort using grid square sizes of 50, 100 (original), 200, 300, and 500μm. The resulting values of EcoScore
are highly correlated. (E) Kaplan-Meier curves display stratification for overall survival using local EcoScore of patients who had optimal debulking surgery (Opt. debulking,
red curves) in the discovery and validation cohorts. Patients who had optimal debulking surgery and a high tumour EcoScore had a statistically similar overall survival










lsource tumours, where it was associated with significantly worse
overall survival (P=0001, Fig. 4F).
In comparison, tumour-level stromal abundance did not pro-
vide the same spatial context for these genomic hallmarks as our
resource definition. The prognostic value of SCNA was greatly re-
duced in the low stromal cell abundance group, with only a bor-
derline significant difference in survival between patients with
high SCNA and those with medium or low SCNA (Fig. S9A). There
was no difference in the prognostic value of mutational burden
when patients were grouped based on stromal cell abundance of
the entire tumour (Fig. S9B). The prognostic values of other ge-omic aberrations (NtAI, LST and HRD-LOH) were not found to dif-
er according to resource (Supplementary Table S2).
We then searched for differences between low and high re-
ource tumours that may explain why mutational burden is prog-
ostic in high resource tumours and SCNA in low resource tu-
ours. There was no significant difference in overall lymphocyte
bundance or the abundance of individual lymphocyte cell types
s enumerated by CIBERSORT [43] (Fig. S10), nor in mutational
urden between these groups (all P > 005, Fig. 4D). Both groups
emonstrated a weak correlation between mutational burden and
ymphocyte abundance, supporting the notion of tumour recogni-
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Fig. 3. Integrating histology-derived ecological measures with cancer genetics. (A) Kaplan-Meier curves show SCNA level, defined by the rate of whole arm or chromosomal
amplification/deletion and available for N=481 patients in the discovery cohort, is not prognostic. Low, medium and high are defined by the 25th and 75th percentiles used
as cut-offs. (B) Kaplan-Meier curves show the prognostic value of mutational burden (MB), defined by the total number of somatic, non-synonymous mutations identified
in the tumour, available for 287 patients in the discovery cohort. Low and high are defined by the 45th percentile used as the cut-off. Numbers outside parentheses
indicate group size and numbers inside parentheses indicate deaths. (C) Swarm plots show the distribution of lymphocyte abundance (left), CD8A expression (middle) and
the cytotoxic immune signature proposed by Davoli et al., 2017 (right), in patients grouped by mutational burden. (D) Scatter plot displays the lack of correlation between
mutational burden and EcoScore in the discovery cohort. (E) A prognostic model combining EcoScore and mutational burden offers substantial improvement in patient
stratification compared to these measures used individually. Patients with a low mutational burden and a high EcoScore (dashed red line) faced the poorest survival rate.
Numbers outside parentheses indicate group size and numbers inside parentheses indicate deaths.
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Fig. 4. Different adaptive strategies in HGSOC based on ecological context. (A) Boxplots show the distribution of four ecological habitats in patients grouped by mutational
burden (low: <45%); high: >45%). The R−H+/− habitats have a significant association with mutational burden as indicated by the two-sided Wilcox test p values. (B)
Example H&E-stained tumour areas from a sample termed low (left) and high (right) resource. (C) Kaplan-Meier curves reveal mutational burden to be prognostic only in
high resource tumours. Numbers outside parentheses indicate group size and numbers inside parentheses indicate deaths. (D) Swarm plots show no significant difference
in lymphocyte abundance (left), mutational burden (middle) and SCNA level (right) between low and high resource tumours. (E) Scatter plots show mutational burden and
lymphocytic abundance are positively correlated in both low and high resource tumours, but SCNA level correlates negatively with lymphocytic abundance only in high
resource tumours. (F) SCNA level is prognostic only in low resource tumours. Numbers outside parentheses indicate group size and numbers inside parentheses indicate
deaths. (G) Box plots show a greater abundance of high hazard habitats in tumours with high resource availability. (H) Box plots show a significantly higher mean expression
of CA9 and VEGFA, taken as surrogates for hypoxia, in low resource tumours. High and low resource is defined by the median value of high resource habitat abundance
in this cohort. (I) A H&E-stained tumour region is shown (top row) along with corresponding ecological habitat classification (middle row) and VEGF protein expression
(bottom row) obtained from automated image alignment of the VEGF IHC-stained section with the H&E-stained section from the same tumour. The low resource habitats
(purple and cyan) spatially correlate with VEGF expression. (J) Boxplots show percentage VEGF positivity in a total of 53,069 low and high resource habitats obtained from
four tumours from the Lan et al. cohort where VEGF IHC-stained sections were available. VEGF expression is significantly higher low resource habitats compared with high
resource ones.




























































































































Eion by immune cells in response to tumour antigen [14] (P < 005,
ig. 4E). In contrast, lymphocyte abundance did not correlate with
CNA in the low resource tumours (Fig. 4E). Although they had a
egative association in the high resource tumours, SCNA was not
linically relevant (Fig. 4E and F). Therefore, the prognostic value of
utational burden and genomic instability was ecological context-
ependent, and cannot be explained by examining the abundance
f lymphocytes and stromal cells alone. The weakness of the cor-
elations found between the mutational burden and lymphocytic
bundance may, in part, be a consequence of a difference in the
pecific locations of the tumour used for sequencing and image
nalysis. In the presence of tumour heterogeneity, such differences
n sampling location are a likely confounders and are a limitation
f the experimental design.
We next examined hazard, indicating co-localization of lym-
hocytes and cancer cells, in the context of tumour resource. Im-
une hazard was significantly higher in high resource tumours
P < 0.0001, Fig. 4G), suggesting that lymphocytes, while not dif-
ering in abundance between high and low resource tumours, ex-
ibited greater co-localization with cancer cells in high resource
umours than low, thus presenting a more effective immune re-
ponse following neoantigen recognition in these tumours. On the
ther hand, a hypoxia gene expression signature that included
EGFA and CA9 [44] was significantly higher in low resource tu-
ours (Fig. 4H). To validate this finding, automated alignment of
EGF IHC-stained tumour sections images to corresponding H&E
mages was performed to obtain the fraction of VEGF-positive cells
n a total of 53,069 high- and low-resource habitats across valida-
ion samples (Supplementary Methods, Fig. 4I, Table S3). Low re-
ource habitats had a higher fraction of VEGF-positive cells com-
ared to high resource habitats (P < 00001, Fig. 4J).
. Discussion
The evolutionary dynamics of neoplastic cells are shaped by the
icroenvironment that defines the selective pressures to which
hey are subjected [15,45]. In this study, we performed an inte-
rative analysis of cancer evolutionary strategies and the microen-
ironmental context in which these strategies excel. Mutations in
athways such as DNA damage repair and DNA replication may ini-
ially increase the overall fitness of cancer, but a high mutational
urden has been linked with the formation of neoantigens attract-
ng immune predation and better patient survival rates [41,46]. In
igh-grade serous ovarian cancer which has the highest disease
ortality among gynaecologic cancers, we evaluated how these
ey strategies of cancer perform under different microenvironmen-
al conditions. By combining spatial and contextual histologic im-
ge analysis of the tumour microenvironment with genomics, we
imed to provide a powerful microenvironmental niche model to
nderstand how the microenvironmental spatial complexity influ-
nces cancer adaptive strategies and progression.
The most significant finding from our study was that spa-
ial architecture of tumour stroma could be a key determinant
n successful adaptation of cancer to overcome microenvironmen-
al constraints including immune surveillance and hypoxia. Spa-
ial variation in resource distribution matters [47,48]. Patchy re-
ources create multiple habitats, which may select for different
lones and may respond differently to therapies. Here tumour re-
ource was defined spatially, with high resource referring to tu-
ours with a large number of endothelial cells and fibroblasts well
istributed into close contact with cancer, potentially fuelling can-
er growth and evolution. Whereas, low resource defines a spatial
ondition corresponding to absence or patchy distribution of stro-
al cells. Our data revealed that low resource tumours with high
rm/chromosomal somatic copy number alterations (arm/chrom
CNA) are highly aggressive, despite SCNAs having no prognosticalue in unselected ovarian cancer. In addition, the significantly
igher hypoxia signature in low resource tumours compared to
igh resource tumours indicates that low resource tumours with
igh arm/chrom SCNA may be driven by rapid selection for alter-
tions in cancer drivers. Genetic diversity of cancer cells as a re-
ult of aneuploidy and genomic instability provides large pheno-
ypic variation and fuels evolution [49,50]. Under stress conditions,
his has been shown to fuel rapid adaptive evolution, leading to
election [51]. Our data further indicated that, although SCNA ap-
eared to be independent of immune abundance in low resource
umours, a lower level of cancer-immune co-localization may add
o the ecological conditions favouring high SCNA. These results
ave significant implications for an important clinical considera-
ion for evaluating the efficacy of emerging molecular therapies
argeting detrimental aneuploidy, such as Hsp90 inhibitors [52],
hich is selecting patients most likely to respond to such thera-
ies. We speculate that patients with low resource tumours, de-
ned based on our spatial and contextual analysis of fibroblast and
ndothelial cell distribution, will be the most likely to respond.
Under the high resource condition, we discovered that low tu-
our mutational burden, but not high SCNA, confers advantages
or cancer cells. Low mutational burden was strongly associated
ith decreasing lymphocytic infiltration estimated from histology.
high mutational burden can generate novel epitopes and gene
roducts that can be recognized as foreign by immune cells [53],
hus stimulating an anti-tumour immune response. While this is in
ine with our observation in the high resource tumours, in low re-
ource tumours high mutational burden was no longer associated
ith prognosis. Given the consistent association between lympho-
ytic infiltration and mutational burden in both low and high re-
ource tumours, we hypothesize that immune tracking of cancer is
ore effective in a high resource environment. In support of this,
e found a significantly higher level of co-localization between
ymphocytes and cancer cells, measured by our spatial definition
f immune hazard, in high resource tumours. A speculation is that
lterations to collagen or extracellular matrix create physical bar-
iers in low resource tumours, manifest as patchy stroma, limiting
ffective immune surveillance by preventing T-cell trafficking into
umour nests [54,55].
The dependence of the prognostic value of mutational bur-
en on the ecological context of stromal resource in our data is
elevant given the consorted efforts underway to identify factors
uch as mutational/neoantigen burden for predicting immunother-
py response [56,57]. Our data also predict that this ecological
ontext for resource may be useful, in combination with esti-
ates of tumour mutational burden, for determining which pa-
ients are most likely to respond to developing immunotherapies to
arget neoantigens. We speculate that patients with high resource
umours will be best suited to personalized therapies such as
eoantigen-specific T-cells or vaccines developed using neoantigen
rediction following whole-exome sequencing of tumour samples
58]. Furthermore, understanding the mechanism by which stromal
omponents affect anti-tumour immune responses may provide an
venue for further, novel therapeutic intervention. Therefore, the
ain novelty and differentiator from previous studies is that our
cological habitat classification reaches beyond a prognostic indi-
ator: it represents biologically relevant cancer-microenvironment
nterplay that, together with cancer genetics, could unveil novel
icroenvironmental determinants of cancer evolution. Taken to-
ether, these data highlighted that both the evolutionary dynam-
cs of the neoplastic cells themselves (cancer cell intrinsic factors),
nd the microenvironment that defines the ecology of those cells
cancer cell extrinsic factors), are important considerations in pre-
icting the future behaviour and clinical response of a tumour [14].
The EcoScore was developed based on this foundation. A high
coScore indicates favourable microenvironments for neoplastic













































Ccells with the ecological balance shifted towards resource-rich en-
vironments. A high EcoScore may be indicative of extensive stro-
mal penetration of cancer cells. Our results showed that empha-
sis should be placed on local/short-range rather than global/long-
range effects of resources and hazards on cancer cells for study-
ing tumour ecology. The local EcoScore was associated with poor
five-year overall survival in two independent cohorts of HGSOC pa-
tients with advanced disease, independent of clinical risk factors
including residual disease after surgery, disease stage, age at diag-
nosis, response to treatment and BRCA1/2 mutation, as well as lym-
phocyte and stromal cell abundance measures [24]. By combining
EcoScore with mutational burden, we identified an aggressive sub-
type that may be the ideal patient subset for new therapeutics and
highlighting opportunities for better classifications by combining
cancer genetics and tumour ecology. In addition, we were able to
identify a subgroup of high-risk patients despite optimal debulking
surgery recognized as arguably the most important prognostic fac-
tor in ovarian cancer [59]. There is an urgent need to identify such
patients [8], because although patients with optimal debulking are
expected to have a better prognosis than patients with subopti-
mal debulking in general, a proportion will face more rapid disease
progression, yet there is no available biomarker for their identifi-
cation.
In summary, our study demonstrated that the ecological bal-
ance defined in the vicinity of cancer cells provides critical context
for cancer cells to assume different evolutionary strategies, which
motivated our development of a new prognostic marker indepen-
dent of known clinical risk factors for HGSOC. The interaction be-
tween cancer cells and their surrounding healthy tissue is vital for
tumour growth and evolution, yet they are often studied in iso-
lation. Our study, although limited by access to large amount of
validation tumour samples and being correlative in nature, pro-
vided new evidence supporting that the clinical consequences of
cancer hallmarks, mutagenesis and aneuploidy, differ under spe-
cific tissue ecological contexts. Under high resource condition, se-
lection may be driven by point mutations, whereas in low resource
tumours, selection is fuelled by aneuploidy. Other limitations of
our study include, firstly, that we used non-synonymous mutation
count as an indicator of tumour mutational burden. This was due
to non-availability of data on synonymous variants, although these
are less likely to have an ecological impact since they do not lead
to neoantigens and thus immunogenicity in the tumour. Second,
our image analysis pipeline detects three cell types only, and cells
such as macrophages and endothelial cells are not explicitly iden-
tified. With the rapid advances now occurring in computer vision,
we expect this limitation will be adequately addressed in the near
future. In addition, our findings could be consolidated by staining
for identifying pro- and anti-tumour immune cells for further clas-
sification of immune hazards. Future work to understand the bio-
logical basis of fundamentally different tumour ecological contexts
and how they alter the evolutionary trajectory of cancer through
distinct mechanisms could pave the way for novel ecological ther-
apies.
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